Highest-materiality recent filing
Elutia receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Aug 6, 2026 for closing bid below $1.00 for 30 consecutive business days.
Elutia signs agreement to sell SimpliDerm business for up to $11M, focuses on NXT-41x launch
Total consideration up to $11M: $8M cash at closing plus up to $3M in technology transfer and commercial milestone payments over 18 months.
Elutia stockholders approve 3M share increase in 2020 Incentive Plan; reelect directors
First Amendment to 2020 Plan increases share authorization by 3M shares, extends termination to June 2036.
Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027
Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.
Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M
Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.
Elutia adopts 2026 Inducement Award Plan, authorizing up to 2M shares for new hire grants
Board adopted Inducement Plan on March 3, 2026; allows equity grants to new employees as hiring inducement without shareholder approval.
Elutia regains full compliance with Nasdaq minimum bid price and MVLS requirements
Received Nasdaq notice on March 2, 2026, confirming compliance with minimum bid price rule (bid ≥ $1.00 for 10 consecutive days).
Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt
Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.
Notice received Dec 23, 2025: MVLS below $35M for 30 consecutive business days.
Elutia receives Nasdaq deficiency notice for bid price below $1.00 per share
Nasdaq notified Elutia on Nov 7, 2025 that its common stock closed below $1.00 for 30 consecutive business days.
Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt
Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.
Elutia appoints medtech veteran Guido Neels to board; Jordan and Zuga resign
Guido J. Neels elected to board effective Oct 9, 2025; appointed to Audit Committee.
Elutia closes $88M sale of BioEnvelope business to Boston Scientific; pivots to NXT-41x
Closed sale of CIED/BioEnvelope business to Boston Scientific for $88M cash; $80.3M paid at closing, $8M escrowed for 12 months.
Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline
Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.
Elutia amends SWK credit facility, capitalizes interest and fees into principal
Fifth Amendment to $25M senior secured term loan capitalizes accrued interest due Aug 2025, $50k amendment fee (June 30, 2025), and $10k amendment fee.
Elutia Q2 BioEnvelope revenue $3.5M (+33% YoY), EluPro sales surge 49% sequentially
EluPro drug-eluting envelope revenue up 49% sequentially; now ~2/3 of BioEnvelope sales; average per-customer spend 130% higher vs legacy CanGaroo.
Elutia annual meeting elects two Class II directors, ratifies PwC as auditor
29,585,703 shares (80.9% of outstanding) present at May 29, 2025 annual meeting.
Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth
Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.
Elutia terminates LeMaitre distribution deal, moves to direct cardiovascular sales
Termination of distribution agreement with LeMaitre Vascular for ProxiCor, VasCure, Tyke products in the U.S.
Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M
Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.
Elutia raises $15M in registered direct offering; sells 5.52M shares at $2.50/share
Gross proceeds of $15.0M from sale of 5,520,000 shares at $2.50 and 480,000 prefunded warrants at $2.499.
Elutia prelim FY2024 net sales $24.4M, down 1% YoY; cardiovascular sales plunge 42%
Preliminary 2024 net sales $24.4M vs $24.7M in 2023, a 1% decline.
Elutia Q3 net sales $5.9M (-3.3%); EluPro adoption accelerates with 100+ VAC submissions
Overall Q3 net sales $5.9M, down 3.3% YoY; BioEnvelope sales down 12% to $2.3M as customers await EluPro.
Elutia amends credit agreement, deferring principal repayments by one year to Nov 2025
Principal repayment commencement deferred from Nov 15, 2024 to Nov 15, 2025.
Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway
Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.
Gross proceeds ~$13.26M from sale of 3,175,000 shares and 725,000 prefunded warrants.
FDA cleared EluPro, first antibiotic-eluting bioenvelope, for pacemakers, defibrillators, neurostimulators, and neuromodulators.
Elutia stockholders elect Maybelle Jordan and W. Matthew Zuga as Class I Directors at annual meeting
Turnout 12,975,682 shares (64.8% of outstanding Class A common stock) at June 6, 2024 annual meeting.
Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024
SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.
Elutia amends credit agreement, reducing minimum revenue covenant to $20M from $41M
Second Amendment with SWK Funding LLC lowers minimum Aggregate Revenue to $20M for trailing twelve months from Q1 2024 onward.
Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024
Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.
Elutia reprices stock options and grants new equity to CEO, CFO, CSO, and other employees
CEO C. Randal Mills' existing options and RSUs vesting thresholds lowered to $6, $10, $14, $18 per share.
Elutia amends Ligand royalty deal; min annual payment rises to $4.4M, $5M milestone waived
Minimum Annual Royalty increased from $2.75M to $4.4M for 2024 and each year thereafter through May 2027.
Received Nasdaq notice on Jan 9, 2024 confirming compliance with board independence rule (majority independent directors).
Elutia regains Nasdaq MVLS compliance; board independence hearing remains
Received Nasdaq notice on Dec 22, 2023 that MVLS requirement met with market value above $35M for 10+ consecutive trading days.
Elutia gets Nasdaq delisting notice over board independence issue; hearing Feb 15, 2024
On Dec 6, 2023, Nasdaq notified Elutia it is not compliant with Board Independence Rule (majority independent). Currently 3/6 directors independent.
Elutia recasts 2022 financials to reflect sale of Orthobiologics business as discontinued operations
Completed sale of Orthobiologics business to Berkeley Biologics LLC on November 8, 2023 for an undisclosed amount.
Elutia closes Orthobiologics sale to Berkeley Biologics for ~$14.6M cash plus up to $20M earn-out
Sale completed Nov 8, 2023; initial cash payment of ~$14.6M after customary adjustments.
Net loss from continuing ops $8.5M ($0.50/sh), improving from $11.0M ($0.81/sh) YoY.
Elutia closes Orthobiologics divestiture for up to $35M in cash proceeds
Upfront payment of $15M due Nov 17, 2023, plus up to $20M earnout over 5 years.
Elutia receives Nasdaq delisting notice for failure to meet MVLS standard; plans to appeal
Received delisting determination from Nasdaq on Nov 1, 2023 for failing to maintain MVLS >= $35M for 10 consecutive days by Oct 31 compliance date.
Elutia raises $10.5M in PIPE with up to $26.2M from warrants; plus divestiture >$60M total cash
Initial gross proceeds ~$10.5M from sale of 7.36M shares/pre-funded warrants and 11.03M common warrants.
Elutia sells Orthobiologics unit to Berkeley Biologics for up to $35M
Upfront cash $15M at close; earn-out payments up to $20M over 5 years (10% of annual revenue from Earn-Out Products, capped at $20M).
Aziyo Biologics rebrands as Elutia; shifts to drug-eluting biomatrices; ticker now ELUT
Name change to Elutia Inc. effective Sept 6, 2023; ticker switches from AZYO to ELUT on Nasdaq on Sept 7.
Aziyo Q2 net sales $10.3M, net loss $10.6M; bone matrix recall drives $3M revenue reversal
Net sales $10.3M, down from $12.6M YoY; recall reversal of $3.0M of Q2 revenue.
Aziyo voluntarily recalls viable bone matrix products after two MTB infections
Voluntary recall of all viable bone matrix products used in orthopedic/spinal procedures.
Aziyo shareholders elect two directors, ratify auditor, approve incentive plan at annual meeting
Elected David Colpman and Kevin Rakin as Class III directors until 2026 annual meeting.
Aziyo reports record Q1 sales $13.1M; Nasdaq warns MVLS below $35M
Net sales rose 14% YoY to record $13.1M; gross margin improved to 49% from 37%.
Aziyo Biologics grants LeMaitre exclusive US distribution rights for cardiovascular products
Three-year exclusive US distribution deal for ProxiCor PC, ProxiCor CTR, Tyke, and VasCure.
Record FY2022 revenue $49.2M; FDA delays CanGaroo RM; Q4 net loss narrows
FY2022 net sales $49.2M (+4% YoY); ex-discontinued FiberCel, current product sales up 16%.
the Company) increased the size of the Board from a total of five to six directors and appointed David Colpman to the Board, effective immediately.
Ronald Lloyd, who will be stepping down as the Company’s President and Chief Executive Officer and as a member of the Board, in each case, effective June 21, 2022
On June 20, 2022, C. Randal Mills, Ph.D., a member of the Board of Directors (the “Board”) of Aziyo Biologics, Inc. (the “Company”), was appointed as the Company’s Interim President and Chief Executive Officer
Max materiality 0.90 · Median 0.70 · Most common event earnings